Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Cumberland Pharmaceuticals Inc. has issued its definitive proxy for the 2026 Annual Meeting, to be held April 21, 2026 at its Nashville headquarters. Shareholders will vote on electing two Class I directors (Kenneth Krogulski and Caroline Young), ratifying Carr, Riggs & Ingram, L.L.C. as auditor for 2026, an advisory “say‑on‑pay” vote on executive compensation, and an advisory vote on how often to hold future say‑on‑pay votes.
The Board recommends voting for all proposals and for holding say‑on‑pay votes every three years. The company discloses 2025 executive pay, highlights 20% revenue growth with higher adjusted earnings and cash flow, and reports a CEO pay ratio of 10:1, with the CEO beneficially owning 38.43% of outstanding common stock.
Cumberland Pharmaceuticals Inc. files its annual report describing a specialty pharmaceutical business focused on hospital acute care, gastroenterology and oncology. The company markets seven FDA-approved brands, including Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Vibativ for serious infections, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia and Talicia for H. pylori.
Cumberland highlights expanding clinical data and labeling for Caldolor, new access agreements for Vibativ, and a U.S. co-commercialization structure for Talicia through Talicia Holdings Inc. Its ifetroban candidate showed positive Phase II results in Duchenne muscular dystrophy cardiomyopathy and is in additional Phase II trials for systemic sclerosis and idiopathic pulmonary fibrosis, supported by orphan, rare pediatric and fast track designations. The company also emphasizes international partnerships, sustainability metrics and disciplined expense management.
Cumberland Pharmaceuticals reported strong 2025 growth with improving profitability and cash generation. Net revenues reached $44.5 million for 2025, up 18% year over year, including $13.7 million in fourth-quarter revenue, a 31% increase over the prior-year quarter. Key brands contributed $10.5 million from Kristalose, $11.9 million from Sancuso, $9.5 million from Vibativ, $4.7 million from Caldolor and $3.3 million from Talicia.
The company’s 2025 net loss narrowed to $2.9 million, a $3.6 million improvement from 2024, while Adjusted Earnings were $1.7 million, a $2.7 million improvement. Operating cash flow turned positive at $4.9 million. At December 31, 2025, Cumberland reported $76.8 million in total assets, $52.3 million in liabilities and $24.9 million in shareholders’ equity, including $11.4 million in cash and a reduced credit facility balance of $5.2 million, down $10 million from year-end 2024.
Strategically, Cumberland expanded Vibativ into China and Saudi Arabia, gained approval for an ibuprofen injection in Mexico, and added Talicia via a co-commercialization agreement. Caldolor received a permanent CMS J-code (J1741), and the ifetroban FIGHT DMD Phase II trial delivered positive top-line results, with the DMD program receiving Orphan Drug, Rare Pediatric Disease and Fast Track designations.
Cumberland Pharmaceuticals Inc. insider A.J. Kazimi has filed a Schedule 13G reporting a significant ownership position in the company’s common stock. Kazimi beneficially owns 5,701,155 shares of Cumberland common stock, representing 38.07% of the outstanding class.
All of these shares are reported with sole voting and sole dispositive power, meaning Kazimi alone can vote and decide whether to sell or hold them. The filing confirms that no other person is identified as sharing voting or investment control over this ownership stake.
Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD). This status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. Cumberland furnished a press release with additional details as an exhibit to this report.
Cumberland Pharmaceuticals director Caroline Young reported a series of small open‑market purchases of the company’s common stock in December 2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows daily acquisitions ranging from $2.24 to $4.32 per share between 12/01/2025 and 12/31/2025, each coded as transaction type “L.”
After the final reported purchase on 12/31/2025 at $3.91 per share, Young beneficially owned 33,309 shares of Cumberland common stock in direct form. A footnote explains that the purchases occurred automatically under a Rule 10b5-1 plan adopted on November 14, 2024, indicating these trades were scheduled in advance.
Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025. The transactions, coded “L,” were executed under a Rule 10b5-1 trading plan that he adopted on November 14, 2024. Individual daily purchases ranged from dozens of shares at prices in the low single digits per share. The most recent reported transaction was on December 31, 2025, when he bought 62 shares at $3.91 each, bringing his directly held stake to 296,538 common shares following that trade.
Cumberland Pharmaceuticals Inc. entered into an amendment to its revolving credit arrangements with Pinnacle Bank. The amendment keeps the aggregate principal funding available at up to $25 million, with $15 million currently available for borrowing and the right for Cumberland to request an additional $10 million. The revolving line continues to be secured by substantially all of the company’s assets.
The facility includes a quarterly-tested Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements. Borrowings will bear interest at Benchmark Term SOFR plus 2.75%. The amendment also extends the credit facility’s maturity to October 1, 2027, giving Cumberland a longer-dated source of revolving liquidity.
Cumberland Pharmaceuticals (CPIX) filed its Q3 2025 report, showing quarterly net revenue of $8.29M versus $9.09M a year ago and a net loss of $1.95M. For the first nine months, revenue rose to $30.84M from $27.43M as growth in Sancuso and Vibativ offset weaker Kristalose.
Sancuso delivered $3.24M in Q3 sales (up year over year) and Vibativ $2.60M, while Kristalose fell to $1.18M amid authorized‑generic shipment delays and higher generic substitution. Cost of products sold was $0.99M, supporting strong gross margin.
Operating cash flow turned positive at $4.93M year‑to‑date, aided by working capital, while cash ended at $15.20M. Debt on the revolving credit facility declined to $5.24M. The company issued 1,000,000 shares via ATM for proceeds of about $5.5M. Shares outstanding were 14,956,627 as of November 5, 2025.
After quarter end, Cumberland and RedHill formed a joint company to co‑commercialize Talicia in the U.S., with Cumberland committing $4M over two years and recording U.S. product sales under an equal net‑revenue share.
Cumberland Pharmaceuticals Inc. filed a current report to furnish a press release dated November 4, 2025. The press release provides a company update and the financial results for the three and nine months ended September 30, 2025. The information is furnished under Item 2.02 regarding results of operations and financial condition and is not deemed filed for liability purposes under Section 18 of the Exchange Act unless later specifically incorporated by reference.